S. V. Deventer

发表

Immunomodulation of Crohn's Disease.

C. Montfrans, T. T. Hove, S. V. Deventer, 2000 .

Cytokine and cytokine receptor polymorphisms in infectious disease

S. V. Deventer, S. Deventer, 2000, Intensive Care Medicine.

Small therapeutic molecules for the treatment of inflammatory bowel disease

Van Deventer, S. V. Deventer, S. Deventer, 2002, Gut.

Up-Regulated During Active Crohn's Disease Endothelial Cells and Macrophages Is IL-18-Binding Protein Expression by

C. Dinarello, Soohyun Kim, M. Kosco‐Vilbois, 2013 .

Immunotherapy of Crohn's Disease

S. V. Deventer, S. Deventer, 2000 .

Tumour necrosis factor and Crohn's disease.

Van Deventer, S. V. Deventer, S. Deventer, 1997 .

Immunomodulation of Crohn's disease using TNF-αneutralizing monoclonal antibodies*

S. V. Deventer, 1997 .

Optimizing Outcomes in Hepatitis C: Is Treatment Beyond 48 Weeks Ever Justified?

Kalden, D. Jewell, P. Lipsky, 2006 .

Inhibitor of TGF-Regulatory T Cell Activity with a Peptide In Vitro and In Vivo Down-Regulation of Borrás

J. Prieto, S. V. Deventer, J. Lasarte, 2008 .

Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohn’s disease patients

D. Hommes, A. V. Kampen, M. Peppelenbosch, 2005, Journal of Molecular Medicine.

Immunomodulation of Crohns Disease

S. V. Deventer, S. Deventer, 2000 .

Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab.

S. V. Deventer, S. Deventer, 1999 .

Anti-TNF antibody treatment of Crohn's disease

S. V. Deventer, S. Deventer, S. V. Deventer, 1999, Annals of the rheumatic diseases.

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

D. Rader, P. Barter, J. Kastelein, 2015, The Lancet.

Inflammatory bowel disease: Future therapies

S. V. Deventer, S. Deventer, 2002 .

The future of inflammatory bowel disease therapy.

S. V. Deventer, S. Deventer, 2002 .

IL-10 gene therapy prevents TNBS-induced colitis

F. Brennan, J. Lindsay, C. Montfrans, 2002, Gene Therapy.

Induction of OVA-specific tolerance by oral administration of Lactococcus lactis secreting OVA

H. Braat, S. V. Deventer, P. Rottiers, 2009 .

Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease

S. V. Deventer, S. Deventer, S. van Deventer, 2001 .

Genomics of the Sepsis Syndrome

P. Stokkers, S. V. Deventer, S. Deventer, 2002 .

Is budesonide an advance in the treatment of Crohn's disease?

S. V. Deventer, S. Deventer, 2001 .

Safety and Efﬁcacy of Recombinant Human Interleukin 10 in Chronic Active Crohn’s Disease

O. Nielsen, S. Nikolaus, S. V. Deventer, 2000 .

Anti-tumour necrosis factor therapy in Crohn's disease: where are we now?

S. V. Deventer, S. Deventer, 2002 .

Inhibition of tumour necrosis factor α converting enzyme as a new therapeutic target in inflammatory bowel disease

S. V. Deventer, S. Deventer, 2002 .

Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4 (cid:1) T cells via modulation of dendritic cell function 1–3

D. Hommes, M. Peppelenbosch, H. Braat, 2004 .

Interleukin 10 gene therapy for Crohn ' s disease

F. Brennan, J. Lindsay, S. V. Deventer, 2007 .

Dichotomy between Lactobacillus rhamnosus and Klebsiella pneumoniae on dendritic cell phenotype and function

M. Peppelenbosch, H. Braat, S. V. Deventer, 2004, Journal of Molecular Medicine.

escalating dose study of alicaforsen enema in active ulcerative colitis

S. V. Deventer, J. Tami, M. Wedel, 2004 .

Therapeutic expression of hairpins targeting Apolipoprotein B100 induces differential changes in murine liver

H. Petry, G. Hooijer, S. V. Deventer, 2013 .

Anti- and proinflammatory effects of interleukin-10 in mild to moderate Crohn's disease

P. Rutgeerts, S. Hanauer, C. Elson, 1999 .